Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?

@article{Livermore2012AreST,
  title={Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?},
  author={David Martin Livermore and Jenny M. Andrews and Peter Hawkey and Pak-Leung Ho and Yoram Keness and Yohei Doi and David L. Paterson and Neil Woodford},
  journal={The Journal of antimicrobial chemotherapy},
  year={2012},
  volume={67 7},
  pages={
          1569-77
        }
}
Recent EUCAST advice asserts that, with low breakpoints, susceptibility results for cephalosporins and carbapenems can be reported 'as found', even for strains with extended-spectrum β-lactamases (ESBLs) and carbapenemases. The CLSI has similar advice, but with higher ceftazidime and cefepime breakpoints than those of EUCAST. Pharmacodynamic and animal data are used to support these views, along with some analysis of clinical case series. We contend that such advice is misguided on three counts… CONTINUE READING
Tweets
This paper has been referenced on Twitter 4 times. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 66 CITATIONS

FILTER CITATIONS BY YEAR

2012
2019

CITATION STATISTICS

  • 4 Highly Influenced Citations

  • Averaged 5 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 38 REFERENCES

Expert Rules in Antimicrobial Susceptibility Testing

  • R Leclercq, R Canton, CG Giske
  • http://www.eucast.org/fileadmin/src/media/PDFs…
  • 2012

Similar Papers

Loading similar papers…